PMID: 9652733Jul 4, 1998Paper

Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1

Leukemia Research
M L LohF O Smith

Abstract

The TEL/AML1 fusion associated with t(12;21)(p13;q22) is the most common gene rearrangement in childhood malignancy, occurring in approximately 25% of pediatric acute lymphoblastic leukemia. The TEL/AML1 rearrangement is cryptic at the cytogenetic level but confers a favorable prognosis. The AML1 gene was first identified by virtue of its involvement in adult and pediatric acute myeloid malignancies associated with t(8;21) and t(3;21)(q26;q22.1). We have therefore determined the frequency of the TEL/AML1 fusion in pediatric myeloid leukemias by RT-PCR analysis. Total RNA was isolated from cryopreserved bone marrow samples of 38 pediatric patients with AML. RNA quality was controlled for by amplification of the TEL gene. An RT-PCR assay was then used to test for the presence of the TEL/AML1 fusion. 29 patients had adequate RNA for analysis. Zero out of 29 pediatric AML patients had evidence for the TEL/AML1 fusion by RT-PCR. The TEL/AML1 fusion does not occur in children with AML and suggests that the TEL/AML1 rearrangement is restricted in pediatric hematologic malignancy to B lineage ALL.

References

Nov 9, 1995·The New England Journal of Medicine·P J Landrigan
Jun 15, 1995·The New England Journal of Medicine·C H Pui
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·T R GolubD G Gilliland
Dec 1, 1996·British Journal of Haematology·R C AguiarN C Cross

❮ Previous
Next ❯

Citations

Jan 21, 2000·Hematological Oncology·S K MaL C Chan
Apr 14, 2005·Seminars in Cancer Biology·Stefan K Bohlander
Jan 16, 2002·Current Opinion in Oncology·Louise KellyD Gary Gilliland
Apr 12, 2001·Cancer Genetics and Cytogenetics·M RieschD R Betts
Apr 24, 2004·Cancer Genetics and Cytogenetics·Pornthep Tiensiwakul
Mar 20, 2003·Cancer Investigation·Joäelle MichaudRobert Escher
Nov 6, 2013·Leukemia & Lymphoma·Katerina KatsibardiFotini Tzortzatou-Stathopoulou
Dec 29, 2000·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·S K RafiM B Qumsiyeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.